Matinas BioPharma (MTNB) Announces Proposed Public Offering of Common Stock

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. In connection with the offering, Matinas BioPharma intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Matinas BioPharma.

Piper Sandler & Co. is acting as the sole lead active bookrunner for the offering. SunTrust Robinson Humphrey is also acting as a bookrunner for the offering.

Matinas BioPharma anticipates using the net proceeds from the offering for ongoing development activities for its product candidates, primarily MAT9001, and for working capital and other general corporate purposes.

A shelf registration statement on Form S-3 (File No. 333-217106) relating to the public offering of the shares of common stock described above was declared effective by the Securities and Exchange Commission (the “SEC”) on April 12, 2017.

You May Also Be Interested In

• DeFi Development Corp. plans $20M preferred stock offering
• Change Agents completes phase 2 of its AI video platform Catch-Up
• Metallus CEO Michael Williams to retire; Kris Westbrooks named successor